Top Digital Pathology Platforms startups
There are 232 Digital Pathology Platforms startups which include PathAI, Aiforia, Aignostics, Nucle AI, Techcyte. Out of these, 108 startups are funded, with 52 having secured Series A+ funding. United States has the most number of companies in Digital Pathology Platforms (86), followed by Germany
(16), and then United Kingdom (14).
Over the past 10 years, an average of 12 new companies have been launched annually. Notably, several of these startups have been founded by alumni of Stanford University, Massachusetts Institute of Technology and University of Toronto.
Here is the list of top Digital Pathology Platforms Startups
1. PathAI
Provider of digital pathology image management system for clinical labs. It offers an AISight is a cloud-native intelligent enterprise workflow solution used by the laboratories and research centers to power their digital pathology workflows and AI applications. It serves as a central hub for case management, image management, and best-in-class artificial intelligence tools to enable multiple histopathology use cases.
Key facts about PathAI
- Founded Year: 2016
- Location: Boston (United States)
- Stage: Series C
- Total Funding till date: $255M
- Investors: General Catalyst, General Atlantic and 22 Others
- Latest Funding Round: Series C, May 18, 2021, $*****
- Tracxn Score: 71/100 What is this?
2. Aiforia
Provider of an AI and cloud-based, deep learning image analysis platform in all therapy areas. It provides analysis of digital pathology images for pathologists and researchers. The products are aiforia create, aiforia on-demand, and aiforia cloud.
Key facts about Aiforia
- Founded Year: 2014
- Location: Helsinki (Finland)
- Stage: Public
- Total Funding till date: $23M
- Investors: Ascend Capital Partners, Businessfinland and 8 Others
- Latest Funding Round: Post IPO, Dec 12, 2025, $*****
- Tracxn Score: 64/100 What is this?
- Competitors Rank: 3 of 329 Competitors
3. Aignostics
Developer of artificial intelligence software for biomedical image analysis applications. This technology processes pathology samples to identify drug targets and biomarkers. The software utilizes foundation models to generate embeddings for downstream analysis of tumor microenvironments. These tools support research in drug development and clinical diagnostics by predicting expression patterns and classifying cell types within tissue images.
Key facts about Aignostics
- Founded Year: 2018
- Location: Berlin (Germany)
- Stage: Series B
- Total Funding till date: $53.9M
- Investors: Wellington Partners Venture Capital, Boehringer Ingelheim Venture Fund and 9 Others
- Latest Funding Round: Series B, Oct 29, 2024, $*****
- Tracxn Score: 64/100 What is this?
- Competitors Rank: 6 of 360 Competitors
4. Nucle AI
AI-assisted platform for image analysis. The platform enables researchers to analyze and predict the tissue and cell architecture from pathology slides. It helps with the discovery of pathology-based spatial biomarkers.
Key facts about Nucle AI
- Founded Year: 2017
- Location: Chicago (United States)
- Stage: Series B
- Total Funding till date: $60M
- Investors: Vertex Ventures Israel, Sanofi Ventures and 9 Others
- Latest Funding Round: Series B, Apr 03, 2024, $*****
- Tracxn Score: 62/100 What is this?
- Competitors Rank: 5 of 329 Competitors
5. Techcyte
Artificial intelligence (AI) based image analysis platform for pathologists. The tool called Techcyte uses several Artificial intelligence (AI) platforms to perform image analysis on digital microscopy images. Also developing AI-based digital analysis tools for hematology tests, cervical cytology tests, ova and parasites (O&P) fecal tests for humans as well as animal samples. The company has collaborated with Motic, a leading provider of whole slide scanners to provide advanced solutions for scanning, image analysis, workflow, and reporting recently.
Key facts about Techcyte
- Founded Year: 2014
- Location: Orem (United States)
- Stage: Series B
- Total Funding till date: $50.4M
- Investors: ARUP Laboratories, Zoetis and 2 Others
- Latest Funding Round: Series B, Apr 30, 2026, $*****
- Tracxn Score: 62/100 What is this?
- Competitors Rank: 6 of 329 Competitors
